What is the right way to administer pegylated liposomal doxorubicin in breast cancer therapy?

J Clin Oncol. 2010 Apr 20;28(12):e193-4; author reply e195-6. doi: 10.1200/JCO.2009.26.8052. Epub 2010 Mar 1.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / administration & dosage*
  • Antibiotics, Antineoplastic / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / secondary
  • Docetaxel
  • Dose-Response Relationship, Drug
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Doxorubicin / analogs & derivatives*
  • Female
  • Humans
  • Maximum Tolerated Dose
  • Polyethylene Glycols / administration & dosage*
  • Polyethylene Glycols / adverse effects
  • Taxoids / administration & dosage
  • Treatment Outcome

Substances

  • Antibiotics, Antineoplastic
  • Taxoids
  • liposomal doxorubicin
  • Docetaxel
  • Polyethylene Glycols
  • Doxorubicin